Factor V Leiden: a disorder of factor V anticoagulant function

被引:43
作者
Castoldi, E [1 ]
Rosing, J [1 ]
机构
[1] Maastricht Univ, Cardiovasc Res Inst, Dept Biochem, NL-6200 MD Maastricht, Netherlands
关键词
activated protein C resistance; factor V Leiden; activated protein C cofactor; anticoagulant factor V;
D O I
10.1097/01.moh.0000130315.41033.32
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Activated protein C (APC) resistance, which is often associated with the factor V R506Q (FV Leiden) mutation, is a common risk factor for venous thrombosis. Study of the mechanism of APC resistance has revealed that coagulation FV stimulates the APC-catalysed inactivation of FVIIIa, and that this anticoagulant function of FV is impaired in FV Leiden. The present review covers the discovery, the physiological significance and the structural requirements of the APC-cofactor activity of FV. Recent findings Recent in vitro and in vivo experiments indicate that the anticoagulant activity of FV is physiologically relevant and that FV plays a major role in the maintenance of the haermostatic balance. Quantitative and functional defects of the APC-cofactor activity of FV lead to increased thrombin generation and are associated with a prothrombotic state. Although the structural requirements for the expression of the APC-cofactor activity of FV are now beginning to be unravelled, the underlying molecular mechanism remains elusive. Summary The APC-cofactor activity of FV and its impairment in FV Leiden can explain the different thrombosis risks associated with heterozygosity, homozygosity and pseudo-homozygosity for FV Leiden. Elucidation of the molecular mechanism of the anticoagulant function of factor V may provide novel targets for the design of antithrombotic drugs.
引用
收藏
页码:176 / 181
页数:6
相关论文
共 44 条
[1]  
Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P193
[2]  
Amano K, 1998, THROMB HAEMOSTASIS, V79, P557
[3]   A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype [J].
Bernardi, F ;
Faioni, EM ;
Castoldi, E ;
Lunghi, B ;
Castaman, G ;
Sacchi, E ;
Mannucci, PM .
BLOOD, 1997, 90 (04) :1552-1557
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   Molecular bases of pseudo-homozygous APC resistance: The compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma [J].
Castoldi, E ;
Kalafatis, M ;
Lunghi, B ;
Simioni, P ;
Ioannou, PA ;
Petio, M ;
Girolami, A ;
Mann, KG ;
Bernardi, F .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :403-406
[6]   Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma [J].
Castoldi, E ;
Rosing, J ;
Girelli, D ;
Hoekema, L ;
Lunghi, B ;
Mingozzi, F ;
Ferraresi, P ;
Friso, S ;
Corrocher, R ;
Tans, G ;
Bernardi, F .
THROMBOSIS AND HAEMOSTASIS, 2000, 83 (03) :362-365
[7]  
CASTOLDI E, 2004, IN PRESS BLOOD, V20
[8]   A novel mutation of Arg306 of factor V gene in Hong Kong Chinese [J].
Chan, WP ;
Lee, CK ;
Kwong, YL ;
Lam, CK ;
Liang, R .
BLOOD, 1998, 91 (04) :1135-1139
[9]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[10]   Molecular recognition in the protein C anticoagulant pathway [J].
Dahlbäck, B ;
Villoutreix, BO .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1525-1534